- £32.57m
- £14.98m
- £1.04m
- 21
- 15
- 38
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 17.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -67.55% | ||
| Return on Equity | -69.68% | ||
| Operating Margin | -1346.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.63 | 0.68 | 0.76 | 1.01 | 1.04 | 2.08 | 6.67 | 15.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ANGLE plc is a United Kingdom-based liquid biopsy company. The Company is engaged in the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy-non-invasive cancer diagnostics. Its platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplexed analysis of nucleic acids and proteins. Its Parsortix PC1 Clinical system captures and harvests circulating CTCs from metastatic breast cancer patients blood for subsequent, user-validated analysis. The Parsortix PC1 Clinical System is a liquid biopsy technology. Its labs in Guildford provide specialist CTC enrichment and analysis services to support translational research studies and pharmaceutical trials. It has developed the Parsortix system, including instruments and one-time use cassettes that can be sold to third-party laboratories for their use in research, pharmaceutical development, or clinical use.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- December 4th, 2003
- Public Since
- March 17th, 2004
- No. of Employees
- 170
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 260,580,547
- Address
- The Surrey Research Park, 10 Nugent Road, GUILDFORD, GU2 7AF
- Web
- https://www.angleplc.com/
- Phone
- +44 1483343434
- Auditors
- PricewaterhouseCoopers LLP
Latest News for AGL
Upcoming Events for AGL
Angle PLC Annual Shareholders Meeting
Half Year 2024 Angle PLC Earnings Release
Similar to AGL
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Advanced Oncotherapy
London Stock Exchange
Aptamer
London Stock Exchange
Belluscura
London Stock Exchange
FAQ
As of Today at 19:02 UTC, shares in Angle are trading at 12.50p. This share price information is delayed by 15 minutes.
Shares in Angle last closed at 12.50p and the price had moved by -27.54% over the past 365 days. In terms of relative price strength the Angle share price has underperformed the FTSE All Share Index by -28.79% over the past year.
The overall consensus recommendation for Angle is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Angle does not currently pay a dividend.
Angle does not currently pay a dividend.
Angle does not currently pay a dividend.
To buy shares in Angle you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 12.50p, shares in Angle had a market capitalisation of £32.57m.
Here are the trading details for Angle:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AGL
Based on an overall assessment of its quality, value and momentum Angle is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Angle is 70.00p. That is 460% above the last closing price of 12.50p.
Analysts covering Angle currently have a consensus Earnings Per Share (EPS) forecast of -£0.07 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Angle. Over the past six months, its share price has underperformed the FTSE All Share Index by -9.2%.
As of the last closing price of 12.50p, shares in Angle were trading -11.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Angle PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 12.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Angle's management team is headed by:
- Garth Selvey - NEC
- Andrew Newland - CEO
- Ian Griffiths - FID
- Jan Groen - NID
- Brian Howlett - NID